DoD awards $1.1M to Seattle’s A-Alpha Bio to hunt antibodies for COVID-19 variants with LLNL collaboration

Seattle biotech A-Alpha Bio received a $1.1 million DoD sub-contract to collaborate with Lawrence Livermore National Laboratory, using its AlphaSeq platform and machine learning to identify high-affinity antibodies against current and future COVID-19 variants.

RRandolph Lopez DDavid Younger AA-Alpha Bio UUniversity of Washington